A completed Phase 3 clinical trial looked at whether semaglutide can improve walking ability in people who have both type 2 diabetes and peripheral arterial disease, a condition that narrows the arteries in the legs and can make walking painful. The results of that trial are now public. This matters to readers who take semaglutide for diabetes or weight management and who also live with leg artery disease, since the drug's effect on physical function, not just blood sugar or body weight, has been an open question until now.
The trial, listed on ClinicalTrials.gov as NCT04560998, compared semaglutide against a placebo in people diagnosed with both type 2 diabetes and peripheral arterial disease (PAD). PAD narrows the arteries that carry blood to the legs, and one of its most common symptoms is pain or cramping in the legs during walking, a symptom that can limit how far or how comfortably someone can move through daily life. Researchers wanted to know whether semaglutide, a drug already used for blood sugar control and weight management, could also ease this walking limitation. The study has now finished, and its results have been posted publicly, which means people with PAD and diabetes, along with their clinicians, can review the findings and consider what they might mean for treatment decisions going forward.
If you live with both type 2 diabetes and peripheral arterial disease, this trial result may be worth bringing up with your doctor at your next visit, since it speaks directly to a symptom, walking limitation, that general diabetes or weight management studies do not usually measure. I would suggest asking your care team how these findings apply to your specific situation before making any changes to your treatment plan. You can also review the full trial record linked above for more detail on the study's design and outcomes. Staying informed about results like these is one practical way to take part in conversations about your own care.
Key details
A completed Phase 3 trial shows semaglutide's effect on PAD walking ability, now public.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-06-04